Table 4 Characteristics of the HIV infection at time of cervical dysplasia diagnosis in relationship with cervical treatment failure

Age at HIV diagnosis

 N

146

80

66

 Mean (SD)

28

29.5 (7.7)

27.8 (8.1)

0.47^a

Risk factor for HIV acquisition

 N

137

75 (100%)

62 (100%)

0.09^b

 Blood transfusion

2

0

2 (3.2%)

 Heterosexual

130

74 (98.7)

56 (90.3)

 IVD

2

1 (1.3%)

1 (1.6%)

 Mother to child

3

0

3 (4.8%)

cART use

146

80 (100%)

66 (100%)

 Yes

124 (84.9%)

69 (86.3%)

55(83.3%)

0.62^b

 No

22 (15.1%)

11(13.7%)

11 (16.7%)

Duration of time using cART at time of dysplasia (month)

 N

124

69

55

 Median (IQR)

34 (10–85)

35 (11–82)

27 (8–104)

0.95^a

Cumulative duration of time treated with cART (month)

 N

124

69

55

 Median(IQR)

23 (7–60)

29 (9–62)

22 (6–61)

0.53^a

HIV classification (CDC)

146

80 (100%)

66 (100%)

 A and B

124 (84.9%)

70 (87.5%)

54 (81.8%)

0.34^b

 C

22 (15.1%)

10 (12.5%)

12 (18.2%)

VL at time of dysplasia diagnosis (copies/ml)

 N

142

79

63

 Median(IQR)

50 (20–646)

50 (20–131)

88 (20–5990)

0.02^a

 ≤ 50

85 (59.9%)

55 (69.6%)

30 (47.6%)

0.008^b

 > 50

57 (40.1%)

24 (30.4%)

33(52.4%)

 ≥ 10 × 5

31 (37.8%)

14 (35%)

17 (40.5%)

Cumulative length of undetectable VL (month)

 N

125

68

57

 Median (IQR)

12 (3–26)

19 (7–42)

5 (0.5–17)

< 0.001^a

N

107

63 (100%)

44 (100%)

0.04^b

 Number of patient having undetectable VL less than 1 year

46

22 (34.9%)

24 (54.9%)

 Number of patient having undetectable VL more than 1 year

61

41 (65.1%)

20 (45.5%)

Maximal VL (copies/ml)

 N

145

79 (100%)

66 (100%)

 Median (IQR)

64,600 (6170–1,87,000)

28,000 (2550–1,20,000)

1,00,000 (1675–2,71,250)

0.002^a

 < 10 × 5

81 (55.9%)

52 (65.8%)

29 (43.9%)

0.08^b

 ≥ 10 × 5

64 (44.1%)

27 (34.2%)

37 (56.1%)

Nadir CD4 at time of dysplasia (cells/mm³)

 N

145

79 (100%)

66 (100%)

 Median(IQR)

207 (102–317)

230 (171–345)

168 (78–290)

0.01^a

 ≥ 200

75 (51.7%)

57 (62.7%)

28 (37.3%)

0.04^b

 < 200

70 (48.3%)

33 (40.5%)

38 (57.6%)

 ≥ 100

110 (75.9%)

66 (83.5%)

44 (66.7%)

0.01^b

 < 100

35 (24.1%)

13 (16.5%)

22 (33.3%)

 ≥ 50

124 (85.5%)

69 (87.3%)

55 (83.3%)

0.49^b

 < 50

21 (14.5%)

10 (12.7%)

11 (16.7%)

CD4/CD8

 N

140

76

64

 Median (IQR)

0.5 (0.25–0.8)

0.6 (0.3–0.85)

0.32 (0.2–0.55)

< 0.001^a

CD4 at the time of the dysplasia (cells/mm³)

 N

142

78 (100%)

64 (100%)

 Median (IQR)

430 (237–556)

491 (380–636)

320 (182–465)

< 0.001^a

 0–200

28 (19.7%)

9 (11%)

19 (29.7%)

< 0.001^b

 200–349

27 (19%)

9 (11.5%)

18 (28.1%)

 350–499

37 (26.1%)

23 (29.5%)

14 (21.9%)

 > 500

50 (35.2%)

37 (47.4%)

13 (20.3%)

Management of the cervical dysplasia

 N

146

80 (100%)

66 (100%)

< 0.001^b

 Follow-up

15 (10.3%)

3 (3.8%)

12 (18.2%)

 Conisation

78 (53.4%)

59 (73.8%)

19 (28.8%)

 Ablative or local treatment

48 32.9%)

14 (17.5%)

34 (51.5%)

 Hysterectomy

5 (6.5%)

4 (5%)

1 (1.5%)